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Abstract
Background: The highly variable expression of SSTR subtypes in pituitary adenomas (PA) may partially explain why the subgroup of
somatotropinomas or other adenomas do not respond to the therapeutic action of currently used long-acting somatostatin analogues like
octreotide or lanreotide.
Material and methods: Our study summarizes the data on expression of all somatostatin receptor subtypes (SSTR 1–5), extended for
2A and 2B SSTR isoforms, revealed by means of immunohistochemistry in dependence to different hormonal phenotype of the tumour.
Results: The pattern of SSTR immunostaining (estimated according to the percentage frequency of appearance) was in acromegaly: SSTR 5
> SSTR 1 > SSTR 2A = SSTR 3 > SSTR 2B, in prolactinomas: SSTR 2B = SSTR 3 = SSTR 5 > SSTR 1 = SSTR 2A, in gonadotropino-
mas: SSTR 3 > SSTR 2B > SSTR 1 = SSTR 2A > SSTR 5, in corticotropinomas: SSTR 2A > SSTR 1 = SSTR 3 > SSTR 5 > SSTR 2B.
In PA immunonegative for pituitary hormones, we noticed only a weak staining of all receptor subtypes including SSTR 4. In plurihormo-
nal adenomas with positive GH phenotype the staining pattern was: SSTR 5 > SSTR 1 = SSTR 2B and in plurihormonal PA with
negative GH phenotype: SSTR 1 = SSTR 5 > SSTR 2A = SSTR 2B = SSTR 3. In plurihormonal adenoma with ACTH immunopositivity,
the staining pattern was: SSTR = SSTR 2A = SSTR 3 = SSTR 5. SSTR 1 and SSTR 5 were the most frequent subtypes of somatostatin
receptor in plurihormonal adenomas without ACTH expression.
Conclusions: Human PA represents a group of tumours with a much more differentiated appearance of somatostatin receptor subtypes.
It is very important to determine the SSTR profile individually for each tumour to make an appropriate decision as to therapeutic strategy
choice. Apart from applying SSTR 2 and SSTR 5-preferring octreotide and lanreotide — newly synthesized multiligand analogues, such as
SOM 230, KE 108, or other SST selective analogues, may represent a further useful approach for the treatment, especially in cases other
than somatotropinoma or thyrotropinoma. (Pol J Endocrinol 2009; 60 (4): 240–251)
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Streszczenie
Wstęp: Duża różnorodność ekspresji podtypów receptora somatostatynowego SSTR 1–5 w gruczolakach przysadki (PA) może częściowo
wyjaśniać, dlaczego w guzach somatotropowych lub innych obserwuje się brak odpowiedzi na działanie analogów somatostatyny
o przedłużonym działaniu, takich jak octreotyd i lanreotyd, wiążących się głównie z podtypem receptora 2 i 5.
Materiał i metody: W pracy podsumowano wyniki badania metodą immunohistochemiczną ekspresji wszystkich podtypów receptora
somatostatynowego SSTR 1–5, łącznie z izoformami 2A i 2B, w zależności od fenotypu hormonalnego guza.
Wyniki: Wzory immunoekspresji SSTR 1–5, określone na podstawie procentowej częstości występowania, przedstawiały się następująco:
w akromegalii — SSTR 5 > SSTR 1 > SSTR 2A = SSTR 3 > SSTR 2B, w guzach prolaktynowych: SSTR 2B = SSTR 3 = SSTR 5 > SSTR 1 =
= SSTR 2A, w guzach gonadotropowych — SSTR 3 > SSTR 2B > SSTR 1 = SSTR 2A > SSTR 5, w guzach kortykotropowych — SSTR 2A
> SSTR 1 = SSTR 3 > SSTR 5 > SSTR 2B. W guzach immunonegatywnych dla hormonów przysadkowych zanotowano jedynie słaby
odczyn dla wszystkich podtypów receptora, łącznie z SSTR 4. W guzach wielohormonalnych GH-dodatnich, ekspresja receptora była
następująca — SSTR 5 > SSTR 1 = SSTR 2B, a w guzach wielohormonalnych GH-ujemnych — SSTR 1 = SSTR 5 > SSTR 2A =
= SSTR 2B = SSTR 3. W guzach wielohormonalnych o fenotypie ACTH-dodatnim — SSTR 1 = SSTR 2A = SSTR 3 = SSTR 5.
W guzach wielohormonalnych ACTH-ujemnych najczęściej występowały SSTR 1 i SSTR 5.
Wnioski: Podtypy receptora somatatostatynowego SSTR 1 i SSTR 5 występują w ludzkich gruczolakach przysadki w sposób bardzo
zróżnicowany. Dlatego też, aby podjąć właściwą decyzję dotyczącą sposobu ich leczenia, należy określić indywidualny dla każdego guza,
profil SSTR. Nowo zsyntetyzowane multiligandy, takie jak SOM 230, KE 180 lub selektywne analogi, mogą być użyteczne w leczeniu
zwłaszcza innych guzów, niż te wydzielające GH lub TSH. (Endokrynol Pol 2009; 60 (4): 240–251)
Słowa kluczowe: podtypy receptora somatostatynowego, gruczolaki przysadki, immunohistochemia
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Introduction
Long-acting somatostatin analogues, octreotide, and
lanreotide are largely used in the medical treatment of
growth hormone-secreting pituitary adenomas (PA) (so-
matotropinomas) in patients suffering from acromega-
ly because they inhibit the enhanced growth hormone
secretion and in some cases cause tumour shrinkage.
The same effectiveness of somatostatin analogues was
observed in a rare subtype of pituitary adenoma, thy-
rotropinoma, secreting thyrotropin (TSH), and led to
a rare form of hyperthyroidism. Somatostatin (SST) and
its analogues act via a specific receptor (SSTR) present
on the target cells. Five subtypes of the SST receptor
have been identified so far, i.e. SSTR 1-5 with two spli-
cing variants (2A and 2B) of the type 2 receptor [1, 2].
These receptors belong to a group of 7 transmembrane
domains linked with the G protein and are encoded by
5 genes which are present on separate chromosomes
[3, 4]. The particular SSTR subtype can occur alone or
coexist together with other subtypes in the same cell.
There could be a considerable variation in SSTR expres-
sion between the different adenoma types and among
tumours of the same type. The diversity and coexisten-
ce of several somatostatin receptor subtypes in one tu-
mour unables unequivocal prediction of which recep-
tor subtype would react with a given somatostatin ana-
logue. This highly variable expression of SSTR subty-
pes in pituitary adenomas may partially explain why
a subgroup of somatotropinomas or other pituitary ade-
nomas do not respond to the therapeutic action of the
currently used long-acting somatostatin analogues:
octreotide and lanreotide. Therefore, apart from apply-
ing SSTR 2 and SSTR 5-preferring octreotide and lanre-
otide — newly synthesized multiligand analogues, such
as SOM 230 (pasireotide), KE 108, or other SST selective
analogues, may represent a further useful approach for
the treatment of pituitary adenomas. Trials with soma-
tostatin/dopamine (SST/DA) chimeras in types of pitu-
itary tumours also have been undertaken [5]. Therefo-
re, it is very important to determine the individual SSTR
profile for each tumour to make an appropriate deci-
sion as to the therapeutic strategy choice. The immu-
nohistochemical (IHC) technique performed on paraf-
fin-embedded tissue specimens obtained from surgical-
ly removed tumours which are routinely used for hi-
stopathological examinations seems the best ex vivo in
vitro method in detecting cellular distribution of SST
receptors [6]. It searches the expression of receptors at
the level of receptor protein and gives us insight into
the receptor’s cellular localization. This method should
be considered supplementary to, or even as effective
as, methods of molecular biology or radiodiagnostic
imaging. The usefulness of this method can even be
considered superior, due to lower costs of reagents (mo-
lecular biology), shorter time of providing results, and
lack of using radioactive reagents (receptor scintigra-
phy). We have already proven this in our previous stu-
dies concerning immunohistochemical detection of
SSTR expression in “clinically non-functioning “ human
pituitary adenomas (CNFPA), adrenal gland tumours,
thyroid tumours, and neuroendocrine tumours using
antibodies specific for a given receptor subtype [7–10].
The aim of this study was to summarize the data on
expression of all somatostatin receptor subtypes (SSTR
1–5), extended for a 2A and 2B SSTR isoforms, by me-
ans of immunohistochemistry in order to differentiate
hormonal phenotype of the pituitary adenoma.
Material and methods
This project received the approval of the Ethics Com-
mittee of the Medical University of Łódź no.: RNN/97/
/06/KE dated 16.05.2006. We investigated 66 pituitary
adenomas removed by transsphenoidal adenomecto-
my. Many of them manifested themselves as clinically
non-functioning pituitary tumours before surgery. Ba-
sed on detailed clinical recognition, hormone levels in
patients’ blood, and detailed immunohistochemical
hormonal estimation after surgery, definitive qualifica-
tion into particular groups of pituitary adenomas was
possible. All samples were immunostained with speci-
fic mono- and polyclonal antibodies directed to pituita-
ry hormones or a subunits to determine the hormonal
phenotype of the adenoma. After final qualification, our
material contained: 9 acromegalic patients (8 female
— F,1 male — M, aged 23–60, mean 43 years), 3 prolacti-
nomas (2 F, 1 M, aged 36–57, mean 46.3 years), 22 speci-
mens recognized as gonadotropinoma (8 women,
14 men, aged 39–73, mean 52 years), 5 patients with Cu-
shing disease (4 women, 1 man, aged 29–47, mean
38.6 years), and 4 patients with hormonally immuno-
negative adenoma (2 women and 2 men, aged 40–72,
mean 57 years). Twenty-three tumours were recogni-
zed as plurihormonal adenomas (10 F, 13 M, aged
41–71, mean 55.6 years). This last group was divided into
4 subgroups, depending on GH and ACTH immuno-
expression. For somatostatin receptor subtype determi-
nation, Bouin-Hollande fixed, dehydrated, and paraf-
fin embedded 8-mm sections were immunostained using
commercially available rabbit polyclonal antisera raised
against carboxyl-terminal fragments of specific human
somatostatin receptor subtypes (GRAMSCH Laboratories,
Schwabhausen, Germany): SSTR 1 (named SS-840 anti-
body, corresponding to amino acid sequence 377–391
of the receptor’s peptide chain), SSTR 2A (SS-800, spe-
cific for 355–369 sequence), SSTR 2B (SS-860, specific for
342–356 sequence), SSTR 3 (SS-850, specific for 381–395
242
Somatostatin receptor expression in human pituitary adenomas Hanna Pisarek et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
sequence), SSTR 4 (SS-880, specific for 374–388 sequen-
ce) and SSTR 5 (SS-890, specific for 350–364 sequence).
The immunohistochemical procedures were performed
as previously described [11]. The working dilution of
antibodies was 1: 1000 (diluted in 0.05 M TRIS buffer,
pH 7.6 containing 2% goat serum). Following overni-
ght incubation at 4°C in a humidified chamber with
primary antibodies, the cells were treated with anti-rab-
bit IgG biotinylated goat antibody (1:800, DAKO, Den-
mark) and streptavidin complex (Strept ABC/HRP,
DAKO, Denmark). The immunoreaction was visualized
with 3.3’-diaminobenzidine (DAB, DAKO, Denmark)
solution. For negative controls, the primary antibody
was omitted and normal goat serum was used.
The immunoreactive intensity for specific receptor
proteins was scored semiquantitatively using a descrip-
tive scale as follows: strong staining (+++), moderate
staining (++), weak staining (+), and trace staining (+/–).
Table I. Expression of somatostatin receptor subtypes in somatotropic pituitary adenomas, determined by immunohistochemistry
method (IHC)
Tabela I. Ekspresja podtypów receptora somatostatynowego SSTR 1–5 w guzach somatotropowych, oceniana metodą
immunohistochemiczną (IHC)
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient phenotype 1 2A 2B 3 4 5
1. 2355 Acromegaly GH+ PRL+ ++ ++/+++ ++ + negative ++/+++
F — 43 years old cytopl/ cytopl/ cytopl/ cytopl cytopl/
mem mem mem mem
2.  2391/3 Acromegaly GH+ LH+ ++ + + ++ negative +/++
F — 23 years old cytopl cytopl cytopl cytopl mem/
cytopl
3.  2507 Acromegaly GH+ PRL+ ++/+++ ++ ++/+++ ++ negative +++
F — 46 years old  aSU+ cytopl cytopl cytopl cytopl cytopl
TSH+single
cells
4.  2356 Acromegaly GH+ PRL+ ++/+++ ++/+++ ++/+++ +/– negative ++/+++
F — 56 years old cytopl mem cytopl cytopl
5.  1543/2 Acromegaly GH+ +/++ +/++ +/++ +/++ negative +++
F — 66 years old cytopl cytopl cytopl cytopl cytopl
6.  2441/3 Acromegaly  GH+ PRL+ + ++ +/– ++ negative ++
F — 60 years old  LH+ cytopl mem/ mem mem/
cytopl cytopl cytopl
7.  1839/4 Acromegaly GH+ PRL+aSU+ ++/+++ +/++ ++/+++ ++ negative ++/+++
M — 59 years old  single cells, mem/ mem/ mem/ mem/ mem/
 TSH+single cells cytopl cytopl cytopl cytopl cytopl
8.  2430/2 Acromegaly GH+ PRL+ ++ ++/+++ +/++ ++ negative ++ cytopl
F — 28 years old LH+ aSU+, cytopl cytopl cytopl cytopl
TSH+ single cells
9.  1539/5 Acromegaly GH+ PRL+ ++ ++ ++ +++ negative ++/+++
F — 30 years old mem/ mem/ mem/ cytopl mem/
cytopl cytopl cytopl cytopl
mem: membranous localization; cytopl: cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+), and pale
staining (+/–)
Only strong (+++) or moderate (++) staining was
considered positive of the given subtype of SSTR in the
further descriptions. Subcellular distribution pattern of
SSTR subtypes — membranous or cytoplasmic — was
also determined.
Results
Somatotropinoma
We observed that SSTR 1, 2A, 2B, 3, and 5 subtypes co-
exist in each of the investigated samples with different
intensities, without SSTR 4 (see Table I). This receptor
subtype did not occur in any of the investigated sam-
ples. In our experiment, we found in the majority of
specimens the cytoplasmic localization of the receptor,
although membrane-localized immunopositivity also
occurred. In 7/9 (77.8%) patients we noticed strong and
moderate immunostaining of SSTR1; in the remaining
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two the reaction was weak to moderate. SSTR 2A and
SSTR3 staining with strong and moderate intensity was
observed in 6/9 (66.6%) of samples. In 3 others the im-
munoreaction was trace to moderate. Strong and mo-
derate intensity of SSTR 2B appeared in 5/9 (55.5%) of
cases. The 4 remaining cases exhibited moderate to pale
reaction. In 8/9 (88.8%) of patients, SSTR 5 immunosta-
ining was strong to moderate, and only one specimen
showed moderate to weak reaction. The pattern of SSTR
expression in acromegaly (as estimated according to the
percentage frequency of appearance) was SSTR 5 >
SSTR 1 > SSTR 2A = SSTR 3 > SSTR 2B.
Prolactinoma
Strong and moderate staining of SSTR 1 and SSTR 2A,
which was distributed both in the cytoplasm and the
membranes or only in the cytoplasm, was shown in
2/3 specimens (66.7%) (Table II). SSTR 2B, 3 and 5 im-
munoreactivity with this grade of intensity was obse-
rved in all three cases (100%) (Fig. 1–6). The SSTR 4 in
all of them was negative. The pattern of immunosta-
ining in prolactinomas was: SSTR 2B = SSTR 3 =
= SSTR 5 > SSTR 1 = SSTR 2A.
Gonadotropinoma
Only 4 out of 22 (18.2%) gonadotropinomas showed
strong and moderate SSTR 1 immunoreaction, and one
expressed this receptor subtype with weak to modera-
te intensity (Table III). The remaining 17 cases were
shown as negative to weak grades of staining. The same
score (18.2%) was observed in a case of SSTR 2A, with
negative to weak immunostaining in the remaining
18 samples. Expressions of SSTR 2B, SSTR 3, and SSTR 5
were roughly similar and represented 5, 6, and 3 out of
22 samples (22.7%, 27.3%, 13.6%) respectively. Four out
of 22 tumours presented SSTR 4 immunopositivity with
trace to weak grades of intensity. In the investigated
adenoma cells with different intensity of immuno-
reaction, cytoplasmic and membrane-localized immu-
nopositivity was observed. We also found a local strong
to moderate staining in the endothelium (endoth) in
one specimen. The pattern of immunostaining in this
subtype of pituitary adenomas was: SSTR 3 > SSTR 2B
> SSTR 1 = SSTR 2A > SSTR 5.
Corticotropinoma
Our experiment demonstrated highly variable expres-
sion of SSTR subtypes in five ACTH–secreting pituitary
adenomas (Table IV). We observed a mixed distribution
pattern of receptors — cytoplasmic and membranous.
Strong and moderate staining of SSTR 1, which was di-
stributed both in the cytoplasm and the membranes, or
in the cytoplasm only, was shown in 4/5 specimens (80%),
SSTR 2A in 5/5 (100%), SSTR 2B in 2/5 (40%), SSTR 3 in
4/5 (80%), and SSTR 5 in 3/5 (60%). In contrast to other
subtypes of pituitary adenomas, SSTR 4 immunoreacti-
vity of this subtype was not negative, as in the majority
of cases, but weak positive in 4/5 (80%). In corticotropi-
noma the SSTR 1, 2A, and 3 seem to be the dominant
forms of somatostatin receptor, with expression pattern:
SSTR 2A > SSTR 1 = SSTR 3 > SSTR 5 > SSTR 2B.
Inactive adenomas
In four pituitary adenomas without immunohistoche-
mical reactivity of any hormone, we noticed trace, weak,
or negative staining in all of the investigated receptor
subtypes, including SSTR 4 (Table V).
Plurihormonal adenomas
Plurihormonal adenoma — GH(+)
This group of adenomas, in spite of expression of GH
and some other pituitary hormones, did not reveal acro-
Table II. Expression of somatostatin receptor subtypes in prolactinomas, determined by IHC
Tabela II. Immunohistochemiczna ocena występowania podtypów receptora somatostatynowego SSTR 1–5 w gruczolakach
prolaktynowych
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient  phenotype 1 2A 2B 3 4 5
1.  2353/2 Prolactinoma PRL+ +/++ + ++ ++ negative +++
F — 46 cytopl/mem cytopl/ cytopl/ cytopl/ cytopl/
years old mem mem mem mem
2. 1058 Prolactinoma PRL+ +++ +++ ++ ++ negative +++
F — 57 cytopl/mem cytopl/ cytopl/ cytopl/ cytopl/
years old mem mem mem mem
3. 1237 Prolactinoma PRL+ ++ +++ ++ +++ negative +++
M — 36 cytopl cytopl cytopl cytopl cytopl
years old
mem: membranous localization; cytopl: cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+), and pale
staining (+/–)
244
Somatostatin receptor expression in human pituitary adenomas Hanna Pisarek et al.
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Figure 1. SSTR 1 expression in a prolactinoma patient with weak to
moderate intensity (no. 2353) (+/++ cytopl-mem) (× 600)
Rycina 1. Ekspresja SSTR 1 w gruczolaku prolaktynowym
o intensywności odczynu od słabej do średniej (nr 2353) (+/++
cytopl-mem) (× 600)
Figure 2. Weak SSTR 2A expression in a prolactinoma patient
(no. 2353) (+ cytopl-mem) (× 600)
Rycina 2. Odczyn SSTR 2A o słabym natężeniu w gruczolaku
prolaktynowym (nr 2353) (+ cytopl-mem) (× 600)
Figure 3. Moderate immunostaining of SSTR 2B in a prolac-
tinoma patient (no. 2353) (++ cytopl-mem) (× 600)
Rycina 3. Umiarkowany odczyn SSTR 2B w gruczolaku
prolaktynowym (nr 2353) (++ cytopl-mem) (× 600)
Figure 4. Moderate SSTR 3 expression in a prolactinoma patient
(no. 2353) (++ cytopl-mem) (× 600)
Rycina 4. Umiarkowana ekspresja SSTR 3 w gruczolaku
prolaktynowym (nr 2353) (++ cytopl-mem) (× 600)
Figure 6. Strong SSTR 5 staining in a prolactinoma patient
(no. 2353) (+++ cytopl-mem) (× 600)
Rycina 6. Silna ekspresja SSTR 5 w gruczolaku prolaktynowym
(nr 2353) (+++ cytopl-mem) (× 600)
Figure 5. Negative SSTR 4 expression in a prolactinoma patient
(no. 2353) (× 400)
Rycina 5. Ujemny odczyn SSTR 4 w gruczolaku prolaktynowym
(nr 2353) (× 400)
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Table III. Expression of somatostatin receptor subtypes in gonadotroph pituitary adenomas, determined by IHC
Tabela III. Występowanie podtypów receptora somatostatynowego SSTR 1–5 w guzach gonadotropowych, oceniane metodą
immunohistochemiczną
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient phenotype 1 2A 2B 3 4  5
1.  2387/3 Gonadotropinoma free b-LH+ ++ + ++ + +/– +/++
M — 64 years old cytopl cytopl cytopl mem/ cytopl mem/
cytopl cytopl
2.  2289 Gonadotropinoma  free b-LH+ +/– + negative ++ negative +/++
M — 41 years old cytopl cytopl mem/ cytopl
cytopl
3.  2395 Gonadotropinoma  free b-LH+ +/++ + + + negative +
F — 44 years old cytopl cytopl cytopl cytopl cytopl
4.  1500 Gonadotropinoma aSU+FSH+ negative +/– +/– negative negative +
F — 56 years old  LH+
5.  1602 Gonadotropinoma FSH+LH+ + + + + negative +
F — 72 years old  aSU+
6.  1476 Gonadotropinoma FSH+ +/– + + +/– negative +
M — 47 years old
7.  1609 Gonadotropinoma FSH+ +/– + +/– +/– + ++
M — 47 years old cytopl cytopl cytopl cytopl cytopl cytopl
8. 1646 Gonadotropinoma aSU+ + +/– + + negative +
M — 47 years old   LH+FSH+
single cells
9.  1802/5 Gonadotropinoma aSU+ FSH+ + + + +++ negative +
M — 47 years old cytopl cytopl cytopl cytopl cytopl
10.  1662/5 Gonadotropinoma FSH+ negative negative +/– negative negative +
M — 48 years old
11.  2299 Gonadotropinoma aSU+ LH+ +++ ++ +++ +++ negative +++
M — 48 years old  single cells mem/ mem mem/ cytopl cytopl
cytopl ++/+++ cytopl ++/+++ ++/+++
++/+++ endoth ++/+++ endoth endoth
endoth endoth
12. 1667/4 Gonadotropinoma aSU+ + +/– negative negative negative +
F — 53 years old FSH+ LH+
13.  1925/2 Gonadotropinoma aSU+ FSH+ +++ +++ ++ ++ negative +
F — 53 years old  LH+ cytopl/ cytopl/ cytopl/ cytopl/ cytopl/
mem mem mem mem mem
14.  1283 Gonadotropinoma FSH+ LH+ + + + +/– negative +
F — 49 years old  aSU+
15.  1825 Gonadotropinoma FSH+ LH+ +++ +++ +++ +++ +/– +++
F — 49 years old  aSU+ single cells cytopl cytopl cytopl cytopl cytopl cytopl
16.  1538/3 Gonadotropinoma free-bLH+ + + + + + +
M — 39 years old
17.  1054 Gonadotropinoma aSU+ +/– +/– + +/– negative +
M — 39 years old
18.  1057 Gonadotropinoma aSU+ + negative +/– +/– negative +
M — 51 years old  FSH+ LH+
19.  1083 Gonadotropinoma aSU+ + + + ? negative +
F — 73 years old
20.  1603/3 Gonadotropinoma aSU+ FSH+ + +/– + + negative +
M — 43 years old
21.  1610/1 Gonadotropinoma aSU+ + + + + negative +
M — 70 years old
22.  2785/2 Gonadotropinoma bSU+ LH+ + ++ ++ ++
M — 59 years old cytopl mem/ cytopl mem negative +
cytopl /cytopl cytopl
mem: membranous localization; cytopl: cytoplasmatic localization; endoth: endothelium; strong staining (+++), moderate staining (++), weak
staining (+), and pale staining (+/–)
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Table IV. Expression of somatostatin receptor subtypes in corticotroph adenomas of pituitary, determined by IHC
Tabela IV. Ekspresja podtypów receptora somatostatynowego SSTR 1–5 w guzach kortykotropowych, oceniana metodą
immunohistochemiczną (IHC)
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient phenotype 1 2A 2B 3  4 5
1. 2340/2 Corticotropinoma ACTH+ +++ +++ ++/+++ +++ + +++
M — 37 years old cytopl cytopl cytopl cytopl cytopl cytopl
2. 1680 Corticotropinoma ACTH+ + ++ ++ ++ +/– +
F — 43 years old cytopl cytopl cytopl cytopl cytopl cytopl
3. 1660/1 Corticotropinoma ACTH+ +++ +++ + +++ +/– +++
F — 47 years old mem/ mem/ mem/ mem/ mem/ mem/
cytopl cytopl cytopl cytopl cytopl cytopl
4. 2385/1 Corticotropinoma ACTH+ +++ +++ + +++ + ++
F — 29 years old mem/ mem/ mem/ mem/ mem/ mem/
cytopl cytopl cytopl cytopl cytopl cytopl
5. 2284/4 Corticotropinoma ACTH+ +++ ++ + +/– negative +
F — 37 years old PRL+(20% of cells) mem/cytopl cytopl cytopl cytopl cytopl
mem: membranous localization; cytopl: cytoplasmatic localization; strong staining (+++), moderate staining (++), weak staining (+), and pale
staining (+/–)
Table V. Expression of somatostatin receptor subtypes in inactive adenomas of the pituitary gland, determined by IHC
Tabela V. Ekspresja SSTR 1–5 w guzach immunonegatywnych dla hormonów przysadkowych
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient  phenotype 1 2A 2B  3  4 5
1.  1128 Adenoma inactivum negative IHC + +/– + negative + +
F — 68 years old
2.  1201 Adenoma inactivum negative IHC + + + + + +
F — 40 years old
3.  1537 Adenoma inactivum negative IHC + + + + + +
M — 72 years old
4.  1800 Adenoma inactivum negative IHC + negative + +/– negative +
M — 48 years old
strong staining (+++), moderate staining (++), weak staining (+), and pale staining (+/–)
megaly or another pituitary hyperfunction. Thus, all of
them also belong to “clinically non-functioning” pitu-
itary adenomas (CNFPA).
In plurihormonal adenomas with positive GH phe-
notype of the tumour we found strong and moderate
intensity of staining both of SSTR 1 and SSTR 2B at
the same level in 3/7 (42.8%) with mixed membrane and
cytoplasmic localization (Table VI). SSTR 2A and
SSTR3 immunopositivity was also at the same low le-
vel in 1/7 (14.3%). In another 4 specimens, weak to mo-
derate staining of SSTR 2A was observed. Negative or
pale SSTR 3 reaction in 4 adenomas was noticed. Only
one of the tumours representing SSTR 4 immunoposi-
tivity was found. SSTR 5 was detected in 4/7 (57.1%)
cases with moderate to strong intensity and in the next
two cases (28.5%), with weak to moderate intensity.
Local strong or moderate staining in the endothelium
was observed in some specimens. The receptors were
distributed mainly in the area of cytoplasm with a few
specimens showing mixed membranous – cytoplasmic
localization.
The staining pattern was: SSTR 5 > SSTR 1 = SSTR
2B (57.1% and 42.8%, respectively).
Plurihormonal adenoma — GH(–)
Cytoplasmic and membranous distribution of somato-
statin receptor subtypes with different intensity was
detected in pituitary plurihormonal adenomas with
negative GH phenotype of the tumour (Table VII).
Strong and moderate immunoreactivity of SSTR 1 and
SSTR 5 was detected in 3/4 (75%) samples. The SSTR
2A, 2B, and 3 staining was defined as strong or mode-
rate in 2 out of 4 examined specimens (50%). No pre-
sence of SSTR 4 was found in 3/4 (75%) patients. In
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Table VI. Expression of somatostatin receptor subtypes in plurihormonal adenomas of the pituitary gland with positive GH
phenotype, determined by IHC
Tabela VI. Ekspresja podtypów receptora somatostatynowego SSTR 1–5 w guzach wielohormonalnych przysadki, GH-
dodatnich, oceniana metodą immunohistochemiczną (IHC)
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient  phenotype 1 2A  2B  3  4 5
1.  2293/1 Plurihormonal adenoma GH+ aSU+ + +/– ++ +/– negative ++/+++
F — 54 years old FSH+ LH+ PRL+ cytopl cytopl cytopl
++ endoth
2.  2294/6B Plurihormonal adenoma GH+ aSU+ LH+ ++ +/–/+ +/– negative negative +/++
M — 41 years old mem/ mem/ cytopl
cytopl cytopl ++
+ endoth
endoth
3.  2295/2 Plurihormonal adenoma GH+ aSU+ PRL+ ++ + ++ negative negative ++
M — 71 years old  FSH+ single cells cytopl cytopl cytopl mem/
LH+single cells +++ +/+++ + cytopl
endoth endoth endoth ++
endoth
4.  2361/4 Plurihormonal adenoma GH+ FSH+ + +/++ negative negative negative +/–
M — 44 years old  LH+aSU+ cytopl cytopl
5.  2452/4 Plurihormonal adenoma GH+ LH+ PRL+ + +/++ +/– + negative ++/+++
F — 69 years old cytopl/ cytopl/ cytopl cytopl
mem mem
6.  2782/2 Plurihormonal adenoma GH +LH+ +/++ +/++ +/–/+ ++ negative +/++
M — 46 years old FSH+ aSU+ mem/ mem/ cytopl mem/ mem/
cytopl cytopl cytopl cytopl
7.  2345 Plurihormonal adenoma GH+ PRL+ +++ ++ +++ + +/– +++
F — 64 years old  LH+ ACTH+ cytopl/ cytopl cytopl/ cytopl cytopl
mem mem
mem: membranous localization; cytopl: cytoplasmatic localization; endoth: endothelium; strong staining (+++), moderate staining (++), weak
staining (+), and pale staining (+/–)
Table VII. Expression of somatostatin receptor subtypes in plurihormonal adenomas of the pituitary gland with GH-
immunonegative reaction, determined by IHC
Tabela VII. Ekspresja podtypów receptora somatostatynowego SSTR 1–5 w guzach wielohormonalnych przysadki, GH-
ujemnych, oceniana metodą immunohistochemiczną (IHC)
No  No of Hormonal  SSTR SSTR SSTR SSTR SSTR SSTR
patient  phenotype 1 2A  2B 3  4 5
1.  1930/1 Plurihormonal adenoma  aSU+ single cells +/– + +/– negative +/– +
M — 62 years old PRL+ ACTH+
2.  2279/2 Plurihormonal adenoma PRL+ ACTH+ +/+++ + +++ ++ negative +/+++
M — 53 years old cytopl cytopl/ endoth cytopl/ cytopl
+++ mem +/+++ mem ++
endoth (+++ cytopl ++ endoth
single cells endoth
cytopl)
+++
endoth
3.  2292/1 Plurihormonal adenoma PRL+ ACTH+ ++ ++ +/–/+ +/–/+ negative ++/+++
F — 57 years old cytopl cytopl cytopl cytopl mem/
cytopl
4. 2286/4 Plurihormonal adenoma PRL+ +++ +++ +++ +++ negative +++
F — 57 years old  ACTH+ cytopl cytopl cytopl cytopl cytopl
mem: membranous localization; cytopl: cytoplasmatic localization; endoth: endothelium; strong staining (+++), moderate staining (++), weak
staining (+), and pale staining (+/–)
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one of them, this subtype of receptor was demonstra-
ted in pale staining (25%). Local strong or moderate sta-
ining in the endothelium was observed in one speci-
men (no. 2279). Summary SSTR 1 and SSTR 5 were the
dominant forms of somatostatin receptor subtypes in
this phenotype of pituitary adenoma. The staining pat-
tern was: SSTR1 = SSTR 5 > SSTR 2A = SSTR 2B =
= SSTR 3 (75% and 50%, respectively).
Plurihormonal adenoma — ACTH(+)
In 6 examined specimens of plurihormonal adenoma
with ACTH immunopositivity, SSTR subtypes 1, 2A, 2B,
3, and 5 appeared and the staining was defined as strong
to moderate in 3/6 specimens (50%) (SSTR 1, 2A, 3, 5)
and in 2/6 (33.3%) patients in case of SSTR 2B (Table
VIII). There was no observed SSTR 4 immunostaining
in 5/6 (83.3%) cases, and in 1 sample the reaction was
pale. In this group of pituitary tumours, as was seen
earlier, we noticed a local strong or moderate staining
in the endothelium of the same specimen (no. 2279).
The receptors were distributed mainly in the area of
the cytoplasm with a few having mixed membranous–
–cytoplasmic localization. The staining pattern was:
SSTR 1 = SSTR 2A = SSTR 3 = SSTR 5 (50%).
Plurihormonal adenoma — ACTH(–)
The plurihormonal adenomas without ACTH expression
were characterized by the coexistence of all the investiga-
ted somatostatin receptor subtypes at variable levels in each
tumour (Table IX). They demonstrated cytoplasmic and/or
membrane-localized immunopositivity. SSTR 1 and SSTR
5 dominated with strong and moderate staining in
3/6 specimens (50%); the remaining specimens had less
marked (moderate to weak) immunopositivity. SSTR 2A,
2B, and 3 subtypes where observed only in 2/6 tumours
(33.3%) with strong to moderate immunoreactivity, while
the remaining tumours represented moderate to weak or
even pale to negative staining. It is interesting that in this
group of pituitary tumours, we observed negative SSTR 3
immunostaining more frequently than in others (50%).
Only one of the tumours represented SSTR 4 immuno-
positivity. SSTR 1 and SSTR 5 were the most frequent sub-
types of somatostatin receptor in this type of pituitary tu-
mour. SSTR 1 = SSTR 5 (50%).
Table VIII. Expression of somatostatin receptor subtypes in plurihormonal adenomas with ACTH immunopositivity, determined
by IHC
Tabela VIII. Ekspresja podtypów receptora somatostatynowego SSTR 1–5 w guzach wielohormonalnych przysadki, ACTH-
dodatnich, oceniana metodą immunohistochemiczną (IHC)
No  No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient phenotype  1 2A  2B  3  4  5
1.  2122/1 Plurihormonal adenoma ACTH+ + ++ + + negative +/–
F — 60 years old PRL+ aSU+ cytopl cytopl cytopl cytopl cytopl
LH+ 5% of cells
2.  2283/5 Plurihormonal adenoma ACTH+ PRL+ +/++ +/–/+ +/–/ + ++/+++ negative +/++
F — 60 years old mem/ cytopl cytopl mem/ cytopl
cytopl cytopl
3.  1930/1 Plurihormonal adenoma ACTH+ PRL+ +/– + +/– negative +/– +
M — 62 years old  aSU+ single cells
4.  2279/2 Plurihormonal adenoma ACTH+ PRL+ +/+++ + +/+++ ++ negative +/+++
M — 53 years old cytopl cytopl/ cytopl cytopl/ cytopl
+++ mem +++ mem ++
endoth  +++ endoth ++ endoth
single cells endoth
(cytopl)
+++
endoth
5. 2292/1 Plurihormonal adenoma ACTH+ PRL+ ++ ++ +/–/+ +/–/+ negative ++/+++
F — 57 years old cytopl cytopl cytopl cytopl mem/
cytopl
6.  2286/4 Plurihormonal adenoma ACTH+ PRL+ +++ +++ +++ +++ negative +++
F — 57 years old cytopl  cytopl  cytopl  cytopl cytopl
mem: membranous localization; cytopl: cytoplasmatic localization; endoth: endothelium; strong staining (+++), moderate staining (++), weak
staining (+), and pale staining (+/–)
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Table IX. Expression of somatostatin receptor subtypes in plurihormonal adenomas without ACTH expression, determined by IHC
Tabela IX. Ekspresja podtypów receptora somatostatynowego SSTR 1–5 w guzach wielohormonalnych przysadki, ACTH-
ujemnych, oceniana metodą immunohistochemiczną (IHC)
No No of Hormonal SSTR SSTR SSTR SSTR SSTR SSTR
patient phenotype 1 2A 2B 3 4 5
1.  2345 Plurihormonal adenoma GH+ PRL+ LH+ +++ ++ +++ + +/– +++
F — 64 years old cytopl/ cytopl cytopl/ cytopl cytopl
mem. mem
2. 2294/6 Plurihormonal adenoma aSU+ LH+ GH+ ++ +/–/+ +/– negative negative +/++
M — 41 years old mem/ mem/ cytopl
cytopl cytopl ++
+ endoth
endoth
3.  2295/2 Plurihormonal adenoma aSU+ GH+ PRL+ ++ + ++ negative negative ++
M — 71 years old cytopl cytopl cytopl mem/
+++ +/+++ + cytopl
endoth endoth endoth ++
endoth
4.  2361/4 Plurihormonal adenoma FSH+ LH+ + +/++ negative negative negative +/–
M — 44 years old GH+ aSU+ cytopl cytopl
5.  2424/4 Plurihormonal adenoma LH+ aSU+ PRL+ + ++ +/– +++ negative +++
M — 44 years old  FSH+ single cells cytopl cytopl mem/ mem/
cytopl cytopl
6. 2782/2 Plurihormonal adenoma LH+ FSH+ aSU+ +/++ +/++ +/–/+ ++ negative +/++
M — 46 years old GH+5% of cells mem/ mem/ cytopl mem/ mem/
cytopl cytopl cytopl cytopl
mem: membranous localization; cytopl: cytoplasmatic localization; endoth: endothelium; strong staining (+++), moderate staining (++), weak
staining (+), and pale staining (+/–)
Discussion
In the present study we have shown the wide distribu-
tion of all of the SSTR subtypes in pituitary adenomas
with variable levels both in different groups of pituita-
ry adenomas as well as in individual tumours. Our re-
sults confirm, in part, previous studies concerning GH-
secreted [6, 12] and clinically non-functioning pituitary
adenomas [6, 9]. Therefore, these two types of adeno-
ma were the most frequently investigated in earlier stu-
dies. In the present study in acromegalic patients, we
observed the following pattern of expression: SSTR 5
> SSTR 1 > SSTR 2A = SSTR 3 > SSTR 2B. Previously,
it was shown that SSTR 2A and SSTR 5 appeared with
100% frequency but SSTR 2B and SSTR 3 were less
expressed. None of the tumours presented SSTR 4 im-
munopositivity [12]. These results are generally in agre-
ement with earlier results of other authors [13–16] al-
though they were led mainly by molecular biology
methods (RT-PCR — reverse transcriptase or real-time
polymerase chain reaction). In 23 somatotropinomas
examined by Taboada et al. [13], SSTR 5 mRNA (mes-
senger ribonucleic acid) was the dominant isoform of
SSTR in 52% of the tumours, while SSTR 2 mRNA was
dominant in 39%. The SSTR pattern observed by the
quoted authors was: SSTR 5 > SSTR 2 > SSTR 3 > >
SSTR 1 > > > SSTR 4. According to Hofland and Lam-
berts [14], in human GH-secreting pituitary adenomas,
both SSTR 2 and SSTR 5 are involved in the regulation
of GH secretion. Using in situ hybridization techniques
with selective oligoprobes, Schaer et al. [15] revealed
a very high incidence of SSTR 5 subtype in growth hor-
mone-producing pituitary adenomas. Nielsen et al. [16]
investigated SSTR expression by combining molecular
biology (RT-PCR) and in vivo receptor scintigraphy in
7 acromegalic patients. SSTR 2 mRNA was present in
all cases, whereas SSTR 4 was absent in all samples. It is
of interest that in the group of acromegalic patients
partially responsive or resistant to long-term treatment
with somatostatin analogues, Matrone et al. [17] demon-
strated the expression of SSTR in 1 in 9/16 (56.25%) ca-
ses. They suggested the potential usefulness, in the tre-
atment of this group of patients, of somatostatin analo-
gues selective for SSTR 1, for example BIM-23745. We
found the expression of SSTR 1 in 77.8% samples of so-
matotropinomas but we did not have full information
about the earlier treatment of the patients.
The group of prolactinomas was scarce because cur-
rently this type of tumour is usually treated pharmaco-
logically with D2 receptor ligands. Only patients who
are resistant to the pharmacological therapy undergo
the pituitary surgery. In our study SSTR 2B, 3, and 5
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were equally expressed (100%) while SSTR 1 and 2A
were rarely observed. In Hofland and Lambert’s study
[14], in prolactinomas, SSTR 5 is the key receptor in re-
gulating responsiveness to SS. SSTR 2 is presented with
low abundance. Pawlikowski [6] summarized the data
from different studies on SSTR expression in prolacti-
nomas. The majority of prolactinomas expressed SSTR
1, 2, and 5, whereas SSTR 3 was detectable only in 1 in
3 cases. SSTR3 was expressed in all of the 3 prolactino-
mas studied by Greenman and Melmed [18] by reverse
transcription coupled to polymerase chain reaction.
SSTR 5 was highly expressed in one prolactinoma, but
the remaining two prolactinomas had low levels of
expression of SSTR 5. RT-PCR quantitative analysis per-
formed by Jaquet et al. [19] demonstrated the presence
of SSTR 5 mRNA in all prolactinomas studied. This re-
ceptor subtype was dominant in 7 of 10 tumours. The
SSTR1 transcript was also highly expressed in these tu-
mours. The SSTR 2 transcripts, although detected in all
tumours, were at a much lower level of expression. To
summarize, high SSTR 5 expression is common for all
the above-mentioned prolactinomas, independently of
the method used.
Gonadotropinoma is usually diagnosed before sur-
gery as a clinically non-functioning pituitary adenoma
(CNFPA), but immunohistochemical examination after
adenomectomy revealed positive staining for LH and
FSH or their aSU and/or b-subunit. Therefore, in this
way we qualified this group of patients as diagnosed
with gonadotroph pituitary adenoma. Our results re-
vealed somatostatin receptor subtypes only in 6 (SSTR
3), 5 (SSTR 2B), 4 (SSTR 1, SSTR 2A) and 3 (SSTR 5) out
of 22 investigated tumours with expression pattern:
SSTR 3 > SSTR 2B > SSTR 1 = SSTR 2A > SSTR 5 (27.3%,
22.7%, 18.2 %, and 13.6%, respectively). This is in agre-
ement with the results of Taboada et al.[13] where SSTR
3 mRNA exhibited the highest quantity in NFPA, follo-
wed by SSTR 2. Our earlier study [9] showed 100% im-
munopositivity of SSTR 2B and SSTR 5; other subtypes
were less abundant. Hofland [14] confirmed the existan-
ce of SSTR 2 in a significant proportion of gonadotro-
phs. Although the dates reported by the above-mentio-
ned authors are not fully concordant, in all of them the
expression of SSTR 4 was scarce. In the heterogenous
group of clinically non-functioning pituitary adenomas,
truly inactive adenomas are next to gonadotropinomas
and plurihormonal adenomas. Somatostatin receptor
subtype immunoreactivity in inactive tumours was ob-
served in almost all specimens but was faintly detecta-
ble. It is interesting that SSTR 4 staining was more fre-
quent than in other tumours with 100% weak immu-
nostaining. This observation corroborates with our ear-
lier study [9]. We noticed a similar, weak SSTR 4 reaction
in 4/5 of patients only in corticotropinomas. In addi-
tion, this type of pituitary adenoma also expressed
multiple receptor subtypes with a frequency of 100%
of SSTR 2A, 80% of SSTR 1 and SSTR 3, 60% of SSTR 5,
and 40% of SSTR 2B. As in the former types of pituitary
tumours, there is no complete agreement in results ob-
tained by different authors [14, 20] although their re-
ports suggest that somatostatin receptor subtype 5 is
the most important in regulating ACTH secretion in
Cushing’s disease. Our findings do not confirm the pre-
valence of SSTR 5 in ACTH–secreting adenomas. Ho-
wever, our group of tumours manifesting themselves
as Cushing’s disease was rather scarce and consequen-
tly our observations are not conclusive. The lower mean
age of patients with Cushing disease (38.6 years) as com-
pared to that with other patients with pituitary tumo-
urs is worth consideration.
This study is the first to describe the distribution of
somatostatin receptor subtypes in pituitary plurihormo-
nal adenomas. Our aim was to answer the question of
whether the immunopositivity of GH or ACTH is lin-
ked to a more abundant expression of particular SSTR
subtypes. Twenty-three patients with plurihormonal
adenomas were divided into 4 subgroups depending
on GH and ACTH immunoexpression. The common
feature for all of them was the frequently marked im-
munopositivity of SSTR 1 and SSTR 5. Especially in the
group of plurihormonal adenomas without GH expres-
sion, we observed an increased appearance of SSTR 1
and SSTR 5. So we can say that in the plurihormonal
adenomas, expression of somatostatin receptor subty-
pes does not depend on GH secretion by tumour cells,
and even contrary, the fact of GH absence in the tumo-
ur promotes to increase SSTR production in the cells. It
is also worth mentioning that SSTR 3 immunonegativi-
ty is more frequent than in other types of tumours
(42.8% and 50% frequency in GH-positive and ACTH-
negative subgroups, respectively).
We conclude that human pituitary adenomas repre-
sent a group of tumours with highly differentiated ap-
pearance of somatostatin receptor subtypes. Depending
on the investigated method used, one can observe the
existence of the same SSTR subtype in the same group
of tumours at variable levels. The molecular biology
method (mainly PCR) is now more often used to inve-
stigate receptor expression but it is burdened with some
doubts. IHC technique gives us information about re-
ceptor expression at the protein level. PCR method gi-
ves results at the level of mRNA. However, despite the
gene expression it could be posttranslational modifica-
tion of SSTR without protein synthesis. Thus, mRNA
detection alone is not sufficient to confirm the presen-
ce of receptor protein, which is the molecular target for
somatostatin and its analogues [6, 21]. Moreover, using
this method we could not obtain the data concerning
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the localization of receptor immunopositivity at the cel-
lular level. Membranous or cytoplasmic receptor prote-
in distribution within the cell can tell us about receptor
activity. Because SSTR belongs to a family of 7 trans-
membrane domains linked with the G protein recep-
tors, one could conclude that only membrane-localized
immunostaining is compatible with the functional role
of somatostatin receptors; earlier experience confirms
this thesis [6, 21, 22].
Conclusions
We conclude that human pituitary adenomas represent
a group of tumours with highly differentiated appearan-
ce of somatostatin receptor subtypes. It is very impor-
tant to determine the individual SSTR profile for each
tumour by means of immunohistochemistry to make
an appropriate decision as to the therapeutic strategy
choice. Apart from applying SSTR 2 and SSTR 5-prefer-
ring octreotide and lanreotide, newly synthesized mul-
tiligand analogues such as SOM 230 (pasireotide), KE 108,
or other SST selective analogues may represent a further
useful approach for treatment, especially in cases other
than GH- or TSH-secreting pituitary adenomas.
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